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ORIGINAL RESEARCH
Background: Neuroleptic malignant syndrome (NMS) is a rare side effect of antipsychotic
therapy characterized by fever, muscular rigidity, altered mental status, increased level of
serum creatinine phosphokinase, and increased number of white blood cells. The mortality
rate of patients with NMS remains elevated.
Methods: We examined the clinical records of patients diagnosed with severe NMS admitted
to the Clinical Toxicology Unit, Florence University Hospital, between 1990 and 2004.
Results: Eight patients presented with this neurological disorder. All were treated with
supportive therapy, which included dantrolene, levodopa/benserazide, benzodiazepines,
metamizole and/or paracetamol, and antibiotics. Five survived and three died. Of the three
deceased, two had large hemorrhages in the gastrointestinal tract, and one had massive liver
damage and diffuse hemorrhages throughout the body.
Conclusion: Our results suggest that gastrointestinal bleeding is a frequent cause of death in
NMS patients. Bleeding may occur as a consequence of commonly accepted medical treatments
(especially the use of cyclooxygenase inhibitors as antipyretic agents) and NMS-induced
changes in blood coagulation status. To increase the survival rate of these patients, it is necessary
to avoid using drugs that may facilitate gastrointestinal lesions and to utilize procedures known
to decrease the risk of bleeding.
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Introduction
Neuroleptic malignant syndrome (NMS) is a rare, potentially fatal complication of
antipsychotic therapy and may occur in patients treated with either typical or atypical
neuroleptic agents (Shalev et al 1989; Robb et al 2000; Stanfield and Privette 2000).
The syndrome is characterized by fever, muscular rigidity, altered mental status,
increased level of serum creatinine phosphokinase, and increased number of white
blood cells (Ebadi et al 1990; Pelonero et al 1998; Adnet et al 2000). It has also been
described after the withdrawal of dopaminergic agents, such as L-dopa or inhibitors
of catechol-o-methyl transferase, in patients affected by parkinsonian disorders
(Friedman et al 1985; Iwuagwu et al 2000). These observations suggest that changes
in dopamine receptor function may be largely responsible for the clinical findings
present in these patients.
The proposed medical treatment of the syndrome is: (1) elimination of neuroleptic
treatment; (2) supportive therapy; (3) administration of dopamine receptor agonists
or agents able to increase the function of the dopaminergic system; (4) administration
of dantrolene, a compound able to inhibit the release of Ca
2+ from sarcoplasmic
reticulum thus reducing muscle tone and heat production; and (5) administration of
antipyretic agents to reduce body temperature (Ward et al 1986; Kaufmann and Wyatt
1987; Rosenberg and Green 1989; Tsutsumi et al 1998). It is widely accepted that
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patients and that the most common causes of death are deep
venous thrombosis with pulmonary embolism, acute renal
failure, pneumonia and other types of pulmonary failure
(adult respiratory distress syndrome especially with
rabdomyolysis), myocardial infarction, and sepsis
(Kaufmann and Wyatt 1987; Shalev et al 1989).
In a retrospective evaluation of the cases admitted to the
Clinical Toxicology Unit, Florence University Hospital, we
found that gastrointestinal bleeding and massive liver failure
with diffuse hemorrhages could result in death. Here we
report our experience and suggest that careful control of
gastrointestinal function and coagulation status may
significantly reduce the mortality rate in NMS patients.
Methods
We examined the clinical records of patients admitted to
the Toxicology Unit of Florence University Hospital
between 1990 and 2004. This unit admits patients with drug
dependence, drug side effects, poisoning, and those who
have attempted suicide. Eight out of fifteen thousand patients
presented a typical diagnosis of NMS with all the key
features of the syndrome as reported in Table 1.
Results
The drug involved and the age and outcome of the eight
NMS diagnosed patients are reported in Table 2. Five of
these patients completely recovered, while three died.
Among the latter three, two were under treatment with
chlorpromazine, and one was treated with levomepromazine
plus amitriptyline (see Table 2). Thus, all the patients with
poor outcomes had been treated with agents able to
antagonize not only dopamine but also muscarinic receptors
(Costa et al 1978; Kwok and Mitchelson 1982). Finally, it
is important to note that no history of gastrointestinal
pathology was previously present in these patients.
Case reports
Case 1
A 31-year-old female with a psychiatric diagnosis of bipolar
disorder was treated with chlorpromazine (300 mg/day),
haloperidol (12 mg/day), diazepam (20 mg/day), promazine
(10 mg/day), and orfenadrine 100 mg/day.
She was found agitated and confused with increased
muscular tone and diffuse tremors. Physical examination
of the abdomen and thorax was negative. Her temperature
was 39.3 °C, heart rate 120 beats per minute with regular
rhythm, and blood pressure 140/80. Laboratory findings
were: serum creatinine phosphokinase (CPK) 1895 U/L,
lactate dehydrogenase 835 U/L, WBC 14 300/µL,
hemoglobin 10.3 g/dL, hematocrit 31%, and platelets
181 000 mm3. The patient’s serum Na+ level was 142, K+ 4,
and Cl– 108 mEq/L. Blood urea nitrogen was 1.37 g/L and
creatinine 6 mg/dL. The brain CT showed no signs of tumors
or cerebral or subarachnoid hemorrhage. A lumbar puncture
showed clear CSF with normal intracranial pressure and no
signs of bacterial or viral infections.
Supportive therapy was started with the administration
of fluids, electrolytes, and antibiotics. After formulation of
the diagnosis, the patient received dantrolene (60 mg
intravenously [IV] every 8 h) and bromocriptine (2.5 mg
orally, every 12 h). For the next two weeks, the patient
improved and was transferred to a psychiatric ward where
she received chlordiazepoxide (100 mg/day). However, her
general condition deteriorated and ten days later she returned
to the Clinical Toxicology Unit unconscious. She had
breathing difficulties, and her serum electrolytes were Na+
176, K
+ 6.5, Cl
– 153 mEq/L, and blood urea nitrogen was
3.17 g/L. She was treated with fluids, nutrients, diuretics,
antibiotics, and cortisol (1 g IV). Within two days her general
condition again transiently improved. Since the patient was
agitated, the psychiatrist prescribed diazepam (20–40 mg/
day) and chlorpromazine (50 mg/day intramusculary [IM]).
Table 1 Criteria used for diagnosis of neuroleptic malignant
syndrome
1. Chronic antipsychotic treatment
2. Fever (above 39 °C)
3. Altered mental status
4. Rigidity and tremors
5. Increased serum creatinine phosphokinase activity (> 1000 U)
6. Leucocytosis (> 10 000/mL)
Table 2 Synopsis of the eight neuroleptic malignant syndrome
reported cases
Poor outcome
Age Drugs involved Outcome
1 31 Haloperidol, chlorpromazine, Death
orphenadrine (gastrointestinal bleeding)
2 43 Levomepromazine, amitryptyline Death (massive liver
necrosis)
3 60 Chlorpromazine, haloperidol, Death (ulcer bleeding,
clopentixol necrotizing enteritis)
Recovery
Age Sex Drugs involved Outcome
4 62 F Haloperidol, clothiapine Recovery
5 31 M Clothiapine Recovery
6 54 M Thioridazine, bromperidol Recovery
7 33 M Pimozide, droperidol Recovery
8 48 M Clomipramine, thioriazine, olanzapine RecoveryTherapeutics and Clinical Risk Management 2005:1(3) 227
Neuroleptic malignant syndrome
The fever returned, her blood pressure suddenly decreased,
and blood hemoglobin content reached 6.5 g/dL with
hematocrit at 19.6%. Partial thromboplastin time (PTT) time
was 40 s. Ranitidine (200 mg IV three times a day) and
packed red cells (5 units in three days) were promptly
administered together with supportive therapy. In the next
few days, the patient had repeated episodes of melena and
emesis with the characteristic “coffee grounds” appearance.
Supportive therapy and packed red cells were repeatedly
administered  but her general condition deteriorated and the
patient died.
Case 2
A 43-year-old man who had been treated with benzo-
diazepine, levomepromazine, and tryciclic antidepressants
for bipolar depression was admitted to the unit. His doctor
reported that in the week before his admission the patient
complained of repeated loss of equilibrium with falls.
On admission, he appeared unresponsive and in a
stuporous state. His blood pressure was 120/80, pulse 100
beats/min with regular rhythm, muscular tone was rigid with
tremor, and his body temperature was 39 °C. An abdominal
examination was unremarkable for acute findings and no
pathological or abnormal sounds were present during
auscultation of the lungs. A few petechiae and ecchymoses
were noticed throughout the body.
Laboratory findings were: CPK 4843 U/L, WBC
16 800/µL, hemoglobin 13.6 g/dL, hematocrit 39%, and
platelets 322 000 mm3. The patient’s serum Na+ level was
154, K+ 3.7, and Cl– 106 mEq/L. Blood urea nitrogen was
0.61 g/L and creatinine 3.4 mg/dL. No alcohol or barbiturates
were detected in his blood. Urine drug screening
demonstrated the presence of benzodiazepines, pheno-
thiazines, and tricyclic antidepressants.
The patient was immediately treated with an infusion of
fluids and antibiotics (cephtriazone 2 g). A few hours later,
when the diagnosis of NMS became clear, dantrolene (60 mg
every 8 h) was administered IV and levodopa/carbidoba
(250/25 mg every 12 h) was administered by nasogastric
tube. Since body temperature increased to 40.6 °C, sodium
metamizole (1 g IV) was also administered along with ice
packing.
On the second day of admission, the patient’s general
condition deteriorated. Blood pressure slowly decreased to
60 mmHg, blood CPK levels reached 135 000 U/L, blood
hemoglobin decreased to 6.9 g/dL, and platelets decreased
to 100 000 mm3. PTT time increased to 43 s and plasma
fibrinogen content to 610 mg/dL. Standard resuscitation
therapy with infusion of plasma-expanders, hydrocortisol
2 g IV, and slow infusion of dopamine was unsuccessfully
attempted. The patient died 36 h after admission to the
hospital. The main findings detected at autopsy were massive
liver necrosis with petechiae diffused in most tissues
including brain.
Case 3
A 60-year-old man suffering from paranoid schizophrenia
had been treated, until a few days before admission, with
chlorpromazine (100 mg/day), haloperidol (5 mg/day),
zuclopentixol (50 mg/day), carbamazepine (800 mg/day),
and chlordiazepoxide (50 mg/day). On the day of admission,
he was rather confused, muscular tone was rigid with
tremors, body temperature 40 °C, blood pressure 120/70,
heart rate 100/min with a normal rhythm. The abdominal
examination was unremarkable for acute findings but
showed an appreciable increase in liver volume. The base
of the right lung was dull with normal fremitus. Laboratory
findings were: CPK 5400 U/L, WBC 14 300/µL, hemoglobin
17.8 g/dL, hematocrit 50%, and platelets 156 000 mm3.
Plasma fibrinogen content was 333 mg/dL and PTT 25.7 s.
The patient’s serum Na
+ level was 144, K
+ 3.35, and Cl
–
107 mEq/L. Blood urea nitrogen was 0.98 g/L and creatinine
2.4 mg/dL. Arterial blood gases were: PaO2 70.1, PaCO2
37.7, pH 7.40. Supportive therapy was immediately started
with infusion of fluids, electrolytes, and antibiotics
(ceftazidime 2 g three times a day). Dantrolene (60 mg every
8 h IV) and levodopa/carbidoba (250/25 mg every 12 h
through the nasogastric tubing) were administered as soon
as the diagnosis of NMS was formulated. To reduce the high
fever, metamizole (1 g IV) along with ice packing was
repeatedly used.
In the next four days, fever remained elevated, muscular
tone increased, and level of consciousness decreased. A
progressive decrease in blood platelet content, together with
an elevation of fibrin degradation products (D-dimer:
1144 ng/mL) suggested activation of fibrinolysis and
possible disseminated intravascular coagulation. The
abdomen of the patient was evaluated during a surgical
consult but, because of the general increase in muscular tone,
it was not possible to reach an acceptable diagnosis.
Seven days after admission, the patient had a massive
hematemesis, his blood pressure decreased to 60 mmHg and,
in spite of standard resuscitation therapy, he died. At autopsy,
gastric and duodenal ulcers were found, together with an
acute necrotizing enterocolitis and an acute purulent
peritonitis. Pulmonary edema was the considered immediate
cause of death.Therapeutics and Clinical Risk Management 2005:1(3) 228
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Discussion
Our clinical observations show that bleeding is an important
cause of death in patients with NMS and suggest that actions
aimed at avoiding or reducing bleeding and gut damage
could significantly improve the prognosis of this
“malignant” disease. Previous reports have shown that death
occurs because of cardiovascular collapse, pulmonary
embolism, aspiration pneumonia, or renal failure due to
rhabdomyolisis (Kaufmann and Wyatt 1987). Other serious
complications in these patients are myocardial infarction,
sepsis, and disseminated intravascular coagulation (Pelonero
et al 1998). Case 2 had massive liver damage and signs of
blood loss, possibly due to intravascular coagulation, while
case 3 had clear laboratory signs of intravascular coagulation
that probably contributed to the development of intestinal
perforation and massive loss of blood.
There are also a number of pharmacological reasons that
could explain why gastrointestinal bleeding was frequent
in our patient series. The most obvious is probably the use
of nonsteriodal antiinflammatory drugs (NSAIDs) to reduce
body temperature. This is a commonly accepted procedure
for the treatment of elevated fever (Kaufmann and Wyatt
1987) in spite of the fact that NSAIDs inhibit prostaglandin
synthesis, thus decreasing epithelial mucus formation and
mucosal resistance to injury. NSAIDs may cause lesions
not only in the stomach, but in the duodenum, ileum, and
colon (Wolfe et al 1999). In our clinical records, NSAID
administration was associated with that of the H2 receptor
antagonist ranitidine, a procedure that was obviously not
sufficient to prevent tissue damage and bleeding. NSAIDs
inhibit both cyclooxygenase (COX) 1 a constitutive enzyme
present in most of the cells, including platelets, and COX 2,
an inducible enzyme particularly abundant in neutrophils
and in macrophages (Vane et al 1998). Inhibition of platelet
function could certainly have facilitated bleeding in NMS
patients (Patrono et al 1985).
Dantrolene was another drug administered to NMS
patients. It has been previously observed that patients treated
with this drug may suffer a number of side effects including
gastric irritation, abdominal cramps, and constipation
(Patrono et al 1985). These side effects are not surprising
since dantrolene inhibits calcium flux across the
sarcoplasmic reticulum and may inhibit the depolarization-
induced contraction of smooth muscles thus changing
gastrointestinal and colon motility (Ward et al 1986).
Dantrolene administration may also cause important liver
damage (Utili et al 1977; Donegan et al 1978), and its use
may certainly be involved in causing the massive liver
necrosis of case 2.
All the patients also received agents able to stimulate
dopamine receptors. Case 1 was treated with bromocriptine
while cases 2 and 3 with L-dopa/benserazide. Dopamine
receptor agonists were administered on the assumption that
they could facilitate recovery. It is indeed widely accepted
that when dopamine is locally injected in the pre-optic
anterior hypothalamus it reduces body temperature (Cox et
al 1978), while neuroleptic injected into the basal ganglia
may cause muscular rigidity and generate heat (Adnet et al
2000). Dopamine interacts with at least 5 receptor subtypes
(Emilien et al 1999) and it is not clear which of them is
involved in human thermoregulation. It is known, however,
that dopamine receptor agonists (including dopamine,
bromocriptine, and apomorphine) affect gastric and
intestinal secretion and motility often leading to emesis
(Morris 1978; Parkes 1981). Thus it is reasonable to assume
that systemic administration of dopamine agents could
increase secretion of the gastrointestinal tract, cause
alteration of the peristalsis and contribute to the fatal
outcome of cases 1 and 3.
Finally, all the patients with fatal outcome had been
treated for prolonged periods (years) and were under
treatment, at the appearance of NMS symptoms, with drugs
able to antagonize muscarinic receptors. Case 1 had received
chlorpromazine together with orfenadrine, case 2 received
levomepromazine and amitryptiline, and case 3 had received
chlorpromazine, zuclopenthixol, and carbamazepine. All
these agents have a significant affinity for muscarinic
receptors (Costa et al 1978; Kwok and Mitchelson 1982). It
is widely accepted that these receptors play a key role in the
control of gastrointestinal motility and secretion
(Stockbrugger 1988; Nelson et al 1996; Ehlert et al 1999),
and that a prolonged treatment with muscarinic receptor
antagonists causes supersensitivity of these receptors. This
supersensitivity may be easily observed as an abstinence
syndrome in patients treated for prolonged periods with
antidepressants. Vomiting and diarrhea together with
perspiration are the main signs of this pathology (Dilsaver
and Greden 1984). It is therefore reasonable to assume that
withdrawal of muscarinic antagonists contributed to an
increase in gastrointestinal motility and secretion in cases 1
and 3 who died with gastrointestinal bleeding.
The three fatal cases described suggest that the mortality
rate is still elevated in patients with severe NMS. They also
suggest that in the management of these patients it may be
useful to: (1) avoid the use of NSAIDs; (2) carefully monitorTherapeutics and Clinical Risk Management 2005:1(3) 229
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blood coagulation status to rapidly detect and possibly
correct signs of intravascular coagulation; and (3) use agents
able to minimize the risk of mucosal damage in the
gastrointestinal tract (proton pump inhibitors and/or
prostaglandin agonists). Finally, the elevated mortality rate
in our patient series in which all the patients received
dantrolene and dopamine receptor agonists suggest that
further clinical studies are necessary before assuming that
the administration of these agents is a useful therapeutic
procedure.
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